019 - Brigatinib shows preclinical promise for aggressive relapsed/refractory AK = LK-positive ALCL

J. Matthews; N. Prokoph; R. Trigg; I. Montes-Mojarro; F. Fend; L. Kenner; B. Geoerger; R. Johnston; M. Murray; L. Brugières; A. Burke; Suzanne D. Turner

doi:10.1016/S0145-2126(22)00213-2

019 - Brigatinib shows preclinical promise for aggressive relapsed/refractory AK = LK-positive ALCL

J. Matthews, N. Prokoph, R. Trigg, I. Montes-Mojarro, F. Fend, L. Kenner, B. Geoerger, R. Johnston, M. Murray, L. Brugières, A. Burke, Suzanne D. Turner

Cancer Research UK Clinical Trials Unit

Research output: Contribution to journal › Abstract › peer-review

Original language	English
Pages (from-to)	S16-S17
Number of pages	2
Journal	Leukemia Research
Volume	121
Issue number	Supplement
DOIs	https://doi.org/10.1016/S0145-2126(22)00213-2
Publication status	Published - 20 Oct 2022
Event	Seventh International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma - The Intercontinental New York Times Square, New York, United States Duration: 20 Oct 2022 → 23 Oct 2022

Access to Document

10.1016/S0145-2126(22)00213-2Licence: None: All rights reserved

https://linkinghub.elsevier.com/retrieve/pii/S0145212622002132Licence: None: All rights reserved

Cite this

@article{392c829cc639446a9c402cdd132e8344,

title = "019 - Brigatinib shows preclinical promise for aggressive relapsed/refractory AK = LK-positive ALCL",

author = "J. Matthews and N. Prokoph and R. Trigg and I. Montes-Mojarro and F. Fend and L. Kenner and B. Geoerger and R. Johnston and M. Murray and L. Brugi{\`e}res and A. Burke and Turner, {Suzanne D.}",

year = "2022",

month = oct,

day = "20",

doi = "10.1016/S0145-2126(22)00213-2",

language = "English",

volume = "121",

pages = "S16--S17",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier",

number = "Supplement",

note = "Seventh International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma ; Conference date: 20-10-2022 Through 23-10-2022",

}

TY - JOUR

T1 - 019 - Brigatinib shows preclinical promise for aggressive relapsed/refractory AK = LK-positive ALCL

AU - Matthews, J.

AU - Prokoph, N.

AU - Trigg, R.

AU - Montes-Mojarro, I.

AU - Fend, F.

AU - Kenner, L.

AU - Geoerger, B.

AU - Johnston, R.

AU - Murray, M.

AU - Brugières, L.

AU - Burke, A.

AU - Turner, Suzanne D.

PY - 2022/10/20

Y1 - 2022/10/20

U2 - 10.1016/S0145-2126(22)00213-2

DO - 10.1016/S0145-2126(22)00213-2

M3 - Abstract

SN - 0145-2126

VL - 121

SP - S16-S17

JO - Leukemia Research

JF - Leukemia Research

IS - Supplement

T2 - Seventh International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma

Y2 - 20 October 2022 through 23 October 2022

ER -